Severity
Moderate
FDA Drug recall · Reported January 27, 2016
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
Pine Pharmaceuticals, LLC recalled Bevacizumab 2 mg/0.08 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- Pine Pharm… - a moderate-severity action.
Bevacizumab 2 mg/0.08 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- Pine Pharm… was recalled by Pine Pharmaceuticals, LLC in January 27, 2016. Reason: Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitre…. Check the official notice for the remedy. Verify recall #D-0583-2016 with the FDA Drug before acting.
The recall
Pine Pharmaceuticals, LLC issued this moderate-severity FDA Drug recall-Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitre….
Sourced from official FDA Drug enforcement records. Verify recall #D-0583-2016 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0583-2016) was formally reported on January 27, 2016, with the manufacturer initiating the action on November 4, 2015. It is classified under Moderate severity (Class II), with a current status of Terminated. Pine Pharmaceuticals, LLC is listed as the recalling firm, operating out of Tonawanda, NY. Federal records list the affected scope as N/A.
The documented reason for this recall is: Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use. Distribution data in the federal record shows the product reached: Nationwide and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,322 medical devices recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
N/A
Related Recalls
6
0 from same agency
Bevacizumab 2 mg/0.08 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0583-2016 |
| Date reported | January 27, 2016 |
| Date initiated | November 4, 2015 |
| Recalling firm | Pine Pharmaceuticals, LLC |
| Firm location | Tonawanda, NY |
| Affected scope | N/A |
| Distribution | Nationwide and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-07-02
· 2026-06-25
· 2026-06-18
GE Medical Systems Information Technologies Inc · 2026-06-03
Medline Industries, LP · 2026-06-03
Compare this recall with Rowenta Recalls Cordless Vacuum Cleaners Due to Risk of Ser… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 27, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.